Serveur d'exploration SRAS

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Evasion by stealth: inefficient immune activation underlies poor T cell response and severe disease in SARS-CoV-infected mice.

Identifieur interne : 001811 ( PubMed/Curation ); précédent : 001810; suivant : 001812

Evasion by stealth: inefficient immune activation underlies poor T cell response and severe disease in SARS-CoV-infected mice.

Auteurs : Jincun Zhao [États-Unis] ; Jingxian Zhao ; Nico Van Rooijen ; Stanley Perlman

Source :

RBID : pubmed:19851468

Descripteurs français

English descriptors

Abstract

Severe Acute Respiratory Syndrome caused substantial morbidity and mortality during the 2002-2003 epidemic. Many of the features of the human disease are duplicated in BALB/c mice infected with a mouse-adapted version of the virus (MA15), which develop respiratory disease with high morbidity and mortality. Here, we show that severe disease is correlated with slow kinetics of virus clearance and delayed activation and transit of respiratory dendritic cells (rDC) to the draining lymph nodes (DLN) with a consequent deficient virus-specific T cell response. All of these defects are corrected when mice are treated with liposomes containing clodronate, which deplete alveolar macrophages (AM). Inhibitory AMs are believed to prevent the development of immune responses to environmental antigens and allergic responses by interacting with lung dendritic cells and T cells. The inhibitory effects of AM can also be nullified if mice or AMs are pretreated with poly I:C, which directly activate AMs and rDCs through toll-like receptors 3 (TLR3). Further, adoptive transfer of activated but not resting bone marrow-derived dendritic cells (BMDC) protect mice from lethal MA15 infection. These results may be relevant for SARS in humans, which is also characterized by prolonged virus persistence and delayed development of a SARS-CoV-specific immune response in individuals with severe disease.

DOI: 10.1371/journal.ppat.1000636
PubMed: 19851468

Links toward previous steps (curation, corpus...)


Links to Exploration step

pubmed:19851468

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Evasion by stealth: inefficient immune activation underlies poor T cell response and severe disease in SARS-CoV-infected mice.</title>
<author>
<name sortKey="Zhao, Jincun" sort="Zhao, Jincun" uniqKey="Zhao J" first="Jincun" last="Zhao">Jincun Zhao</name>
<affiliation wicri:level="1">
<nlm:affiliation>Department of Microbiology, University of Iowa, Iowa City, Iowa, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Microbiology, University of Iowa, Iowa City, Iowa</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Zhao, Jingxian" sort="Zhao, Jingxian" uniqKey="Zhao J" first="Jingxian" last="Zhao">Jingxian Zhao</name>
</author>
<author>
<name sortKey="Van Rooijen, Nico" sort="Van Rooijen, Nico" uniqKey="Van Rooijen N" first="Nico" last="Van Rooijen">Nico Van Rooijen</name>
</author>
<author>
<name sortKey="Perlman, Stanley" sort="Perlman, Stanley" uniqKey="Perlman S" first="Stanley" last="Perlman">Stanley Perlman</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2009">2009</date>
<idno type="RBID">pubmed:19851468</idno>
<idno type="pmid">19851468</idno>
<idno type="doi">10.1371/journal.ppat.1000636</idno>
<idno type="wicri:Area/PubMed/Corpus">001811</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001811</idno>
<idno type="wicri:Area/PubMed/Curation">001811</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001811</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">Evasion by stealth: inefficient immune activation underlies poor T cell response and severe disease in SARS-CoV-infected mice.</title>
<author>
<name sortKey="Zhao, Jincun" sort="Zhao, Jincun" uniqKey="Zhao J" first="Jincun" last="Zhao">Jincun Zhao</name>
<affiliation wicri:level="1">
<nlm:affiliation>Department of Microbiology, University of Iowa, Iowa City, Iowa, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Microbiology, University of Iowa, Iowa City, Iowa</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Zhao, Jingxian" sort="Zhao, Jingxian" uniqKey="Zhao J" first="Jingxian" last="Zhao">Jingxian Zhao</name>
</author>
<author>
<name sortKey="Van Rooijen, Nico" sort="Van Rooijen, Nico" uniqKey="Van Rooijen N" first="Nico" last="Van Rooijen">Nico Van Rooijen</name>
</author>
<author>
<name sortKey="Perlman, Stanley" sort="Perlman, Stanley" uniqKey="Perlman S" first="Stanley" last="Perlman">Stanley Perlman</name>
</author>
</analytic>
<series>
<title level="j">PLoS pathogens</title>
<idno type="eISSN">1553-7374</idno>
<imprint>
<date when="2009" type="published">2009</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Animals</term>
<term>Clodronic Acid (administration & dosage)</term>
<term>Dendritic Cells (immunology)</term>
<term>Dendritic Cells (physiology)</term>
<term>Disease Progression</term>
<term>Immune Evasion (immunology)</term>
<term>Immune Evasion (physiology)</term>
<term>Liposomes (therapeutic use)</term>
<term>Lymphocyte Activation (immunology)</term>
<term>Macrophages, Alveolar (drug effects)</term>
<term>Macrophages, Alveolar (pathology)</term>
<term>Mice</term>
<term>Mice, Inbred BALB C</term>
<term>Mice, Inbred C57BL</term>
<term>Myeloablative Agonists (pharmacology)</term>
<term>SARS Virus (immunology)</term>
<term>Severe Acute Respiratory Syndrome (drug therapy)</term>
<term>Severe Acute Respiratory Syndrome (immunology)</term>
<term>Severe Acute Respiratory Syndrome (mortality)</term>
<term>Severe Acute Respiratory Syndrome (prevention & control)</term>
<term>T-Lymphocytes (immunology)</term>
<term>T-Lymphocytes (physiology)</term>
<term>Virus Latency (drug effects)</term>
<term>Virus Latency (immunology)</term>
<term>Virus Latency (physiology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr">
<term>Acide clodronique (administration et posologie)</term>
<term>Activation des lymphocytes (immunologie)</term>
<term>Agonistes myélo-ablatifs (pharmacologie)</term>
<term>Animaux</term>
<term>Cellules dendritiques (immunologie)</term>
<term>Cellules dendritiques (physiologie)</term>
<term>Latence virale ()</term>
<term>Latence virale (immunologie)</term>
<term>Latence virale (physiologie)</term>
<term>Liposomes (usage thérapeutique)</term>
<term>Lymphocytes T (immunologie)</term>
<term>Lymphocytes T (physiologie)</term>
<term>Macrophages alvéolaires ()</term>
<term>Macrophages alvéolaires (anatomopathologie)</term>
<term>Souris</term>
<term>Souris de lignée BALB C</term>
<term>Souris de lignée C57BL</term>
<term>Syndrome respiratoire aigu sévère ()</term>
<term>Syndrome respiratoire aigu sévère (immunologie)</term>
<term>Syndrome respiratoire aigu sévère (mortalité)</term>
<term>Syndrome respiratoire aigu sévère (traitement médicamenteux)</term>
<term>Virus du SRAS (immunologie)</term>
<term>Échappement immunitaire (immunologie)</term>
<term>Échappement immunitaire (physiologie)</term>
<term>Évolution de la maladie</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en">
<term>Clodronic Acid</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr">
<term>Acide clodronique</term>
</keywords>
<keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr">
<term>Macrophages alvéolaires</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en">
<term>Macrophages, Alveolar</term>
<term>Virus Latency</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en">
<term>Severe Acute Respiratory Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr">
<term>Activation des lymphocytes</term>
<term>Cellules dendritiques</term>
<term>Latence virale</term>
<term>Lymphocytes T</term>
<term>Syndrome respiratoire aigu sévère</term>
<term>Virus du SRAS</term>
<term>Échappement immunitaire</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en">
<term>Dendritic Cells</term>
<term>Immune Evasion</term>
<term>Lymphocyte Activation</term>
<term>SARS Virus</term>
<term>Severe Acute Respiratory Syndrome</term>
<term>T-Lymphocytes</term>
<term>Virus Latency</term>
</keywords>
<keywords scheme="MESH" qualifier="mortality" xml:lang="en">
<term>Severe Acute Respiratory Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="mortalité" xml:lang="fr">
<term>Syndrome respiratoire aigu sévère</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en">
<term>Macrophages, Alveolar</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr">
<term>Agonistes myélo-ablatifs</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en">
<term>Myeloablative Agonists</term>
</keywords>
<keywords scheme="MESH" qualifier="physiologie" xml:lang="fr">
<term>Cellules dendritiques</term>
<term>Latence virale</term>
<term>Lymphocytes T</term>
<term>Échappement immunitaire</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en">
<term>Dendritic Cells</term>
<term>Immune Evasion</term>
<term>T-Lymphocytes</term>
<term>Virus Latency</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en">
<term>Severe Acute Respiratory Syndrome</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en">
<term>Liposomes</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr">
<term>Syndrome respiratoire aigu sévère</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr">
<term>Liposomes</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Animals</term>
<term>Disease Progression</term>
<term>Mice</term>
<term>Mice, Inbred BALB C</term>
<term>Mice, Inbred C57BL</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr">
<term>Animaux</term>
<term>Latence virale</term>
<term>Macrophages alvéolaires</term>
<term>Souris</term>
<term>Souris de lignée BALB C</term>
<term>Souris de lignée C57BL</term>
<term>Syndrome respiratoire aigu sévère</term>
<term>Évolution de la maladie</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Severe Acute Respiratory Syndrome caused substantial morbidity and mortality during the 2002-2003 epidemic. Many of the features of the human disease are duplicated in BALB/c mice infected with a mouse-adapted version of the virus (MA15), which develop respiratory disease with high morbidity and mortality. Here, we show that severe disease is correlated with slow kinetics of virus clearance and delayed activation and transit of respiratory dendritic cells (rDC) to the draining lymph nodes (DLN) with a consequent deficient virus-specific T cell response. All of these defects are corrected when mice are treated with liposomes containing clodronate, which deplete alveolar macrophages (AM). Inhibitory AMs are believed to prevent the development of immune responses to environmental antigens and allergic responses by interacting with lung dendritic cells and T cells. The inhibitory effects of AM can also be nullified if mice or AMs are pretreated with poly I:C, which directly activate AMs and rDCs through toll-like receptors 3 (TLR3). Further, adoptive transfer of activated but not resting bone marrow-derived dendritic cells (BMDC) protect mice from lethal MA15 infection. These results may be relevant for SARS in humans, which is also characterized by prolonged virus persistence and delayed development of a SARS-CoV-specific immune response in individuals with severe disease.</div>
</front>
</TEI>
<pubmed>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">19851468</PMID>
<DateCompleted>
<Year>2009</Year>
<Month>12</Month>
<Day>29</Day>
</DateCompleted>
<DateRevised>
<Year>2019</Year>
<Month>12</Month>
<Day>10</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1553-7374</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>5</Volume>
<Issue>10</Issue>
<PubDate>
<Year>2009</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>PLoS pathogens</Title>
<ISOAbbreviation>PLoS Pathog.</ISOAbbreviation>
</Journal>
<ArticleTitle>Evasion by stealth: inefficient immune activation underlies poor T cell response and severe disease in SARS-CoV-infected mice.</ArticleTitle>
<Pagination>
<MedlinePgn>e1000636</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.ppat.1000636</ELocationID>
<Abstract>
<AbstractText>Severe Acute Respiratory Syndrome caused substantial morbidity and mortality during the 2002-2003 epidemic. Many of the features of the human disease are duplicated in BALB/c mice infected with a mouse-adapted version of the virus (MA15), which develop respiratory disease with high morbidity and mortality. Here, we show that severe disease is correlated with slow kinetics of virus clearance and delayed activation and transit of respiratory dendritic cells (rDC) to the draining lymph nodes (DLN) with a consequent deficient virus-specific T cell response. All of these defects are corrected when mice are treated with liposomes containing clodronate, which deplete alveolar macrophages (AM). Inhibitory AMs are believed to prevent the development of immune responses to environmental antigens and allergic responses by interacting with lung dendritic cells and T cells. The inhibitory effects of AM can also be nullified if mice or AMs are pretreated with poly I:C, which directly activate AMs and rDCs through toll-like receptors 3 (TLR3). Further, adoptive transfer of activated but not resting bone marrow-derived dendritic cells (BMDC) protect mice from lethal MA15 infection. These results may be relevant for SARS in humans, which is also characterized by prolonged virus persistence and delayed development of a SARS-CoV-specific immune response in individuals with severe disease.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Zhao</LastName>
<ForeName>Jincun</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Department of Microbiology, University of Iowa, Iowa City, Iowa, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Zhao</LastName>
<ForeName>Jingxian</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Van Rooijen</LastName>
<ForeName>Nico</ForeName>
<Initials>N</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Perlman</LastName>
<ForeName>Stanley</ForeName>
<Initials>S</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>P01 AI060699</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D023362">Evaluation Study</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2009</Year>
<Month>10</Month>
<Day>23</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>PLoS Pathog</MedlineTA>
<NlmUniqueID>101238921</NlmUniqueID>
<ISSNLinking>1553-7366</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008081">Liposomes</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019653">Myeloablative Agonists</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0813BZ6866</RegistryNumber>
<NameOfSubstance UI="D004002">Clodronic Acid</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D004002" MajorTopicYN="N">Clodronic Acid</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D003713" MajorTopicYN="N">Dendritic Cells</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D057131" MajorTopicYN="N">Immune Evasion</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D008081" MajorTopicYN="N">Liposomes</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D008213" MajorTopicYN="N">Lymphocyte Activation</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D016676" MajorTopicYN="N">Macrophages, Alveolar</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D019653" MajorTopicYN="N">Myeloablative Agonists</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D045169" MajorTopicYN="N">Severe Acute Respiratory Syndrome</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
<QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D013601" MajorTopicYN="N">T-Lymphocytes</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D017735" MajorTopicYN="N">Virus Latency</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="received">
<Year>2009</Year>
<Month>07</Month>
<Day>07</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted">
<Year>2009</Year>
<Month>09</Month>
<Day>25</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez">
<Year>2009</Year>
<Month>10</Month>
<Day>24</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2009</Year>
<Month>10</Month>
<Day>24</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2009</Year>
<Month>12</Month>
<Day>30</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">19851468</ArticleId>
<ArticleId IdType="doi">10.1371/journal.ppat.1000636</ArticleId>
<ArticleId IdType="pmc">PMC2762542</ArticleId>
</ArticleIdList>
<ReferenceList>
<Reference>
<Citation>J Virol. 2005 Jun;79(12):7819-26</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15919935</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Immunol. 2005 Jun 15;174(12):7977-85</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15944304</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Blood. 2005 Oct 1;106(7):2366-74</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15860669</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Virol. 2005 Nov;79(21):13800-5</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16227300</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Leukoc Biol. 2005 Dec;78(6):1273-80</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16204643</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Immunity. 2005 Dec;23(6):649-59</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16356862</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Virol. 2006 Mar;80(5):2506-14</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16474157</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Immunol. 2006 Mar 15;176(6):3578-84</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16517726</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Immunity. 2006 Apr;24(4):366-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16618595</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Allergy Clin Immunol. 2006 May;117(5):979-87; quiz 988</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16675322</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Gen Virol. 2006 Jul;87(Pt 7):1953-60</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16760397</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Immunology. 1999 Oct;98(2):181-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10540216</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Immunol. 2000 Aug 1;165(3):1182-90</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10903715</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Leukoc Biol. 2002 Oct;72(4):621-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12377929</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Immunity. 2003 Feb;18(2):265-77</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12594953</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Nature. 2003 Mar 13;422(6928):169-73</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12634787</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Lancet. 2003 Apr 19;361(9366):1319-25</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12711465</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Lancet. 2003 May 24;361(9371):1767-72</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12781535</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>BMJ. 2003 Jun 21;326(7403):1358-62</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12816821</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Immunol. 2003 Jul 1;171(1):27-31</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12816979</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Exp Med. 2003 Aug 18;198(4):615-21</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12925677</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Emerg Infect Dis. 2004 Jan;10(1):20-4</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15078592</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Proc Natl Acad Sci U S A. 2004 Jun 8;101(23):8670-5</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15163797</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Immunol. 2004 Jul 15;173(2):1209-18</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15240712</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Science. 2004 Aug 20;305(5687):1153-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15326355</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Nat Immunol. 2004 Oct;5(10):987-95</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15454922</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Virology. 2004 Nov 10;329(1):11-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15476870</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Emerg Infect Dis. 2004 Sep;10(9):1550-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15498155</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Infect Dis. 2004 Nov 15;190(10):1841-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15499542</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Immunol Methods. 1979;27(2):189-98</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">110886</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell Immunol. 1980 Mar 1;50(1):210-5</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">6156769</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Antivir Chem Chemother. 2006;17(5):275-84</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17176632</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>PLoS Pathog. 2007 Jan;3(1):e5</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17222058</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Biochem Biophys Res Commun. 2007 Jul 6;358(3):716-21</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17506989</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Science. 2007 Jun 15;316(5831):1628-32</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17569868</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Exp Med. 2007 Jul 9;204(7):1625-36</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17606632</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Virol. 2007 Aug;81(16):8692-706</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17537853</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Vaccine. 2007 Sep 28;25(39-40):6981-91</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17709158</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Nat Rev Immunol. 2008 Feb;8(2):142-52</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18204469</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Infect Disord Drug Targets. 2007 Dec;7(4):336-43</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18220965</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Virus Res. 2008 Apr;133(1):101-12</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17451827</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cell. 2008 Apr 18;133(2):235-49</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18423196</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Virol. 2008 May;82(10):4908-19</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18353940</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Am J Pathol. 2008 Jun;172(6):1625-37</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18467696</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Expert Opin Investig Drugs. 2008 Jul;17(7):1051-65</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18549341</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Exp Med. 2008 Jul 7;205(7):1635-46</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18591411</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Nat Immunol. 2008 Sep;9(9):1074-83</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18660812</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>PLoS Pathog. 2008 Dec;4(12):e1000240</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19079579</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Virol. 2009 Feb;83(3):1492-500</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19019963</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Exp Med. 2009 Jan 16;206(1):79-87</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19139171</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Virol. 2009 Apr;83(7):3039-48</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19004938</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Exp Immunol. 1986 Feb;63(2):261-70</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">3516464</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Exp Med. 1988 Feb 1;167(2):262-74</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">3162253</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Exp Med. 1989 Aug 1;170(2):499-509</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">2526847</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Immunol. 1991 Jul 1;147(1):144-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">1904899</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Exp Med. 1993 Feb 1;177(2):397-407</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">8426110</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Exp Med. 1993 Jun 1;177(6):1773-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">8496690</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Immunology. 1993 Oct;80(2):266-72</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">7903277</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Immunol Methods. 1994 Sep 14;174(1-2):83-93</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">8083541</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Immunol. 1994 Oct 15;153(8):3426-39</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">7523493</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Exp Med. 1995 Apr 1;181(4):1275-83</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">7699319</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Eur Respir J. 1994 Dec;7(12):2124-30</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">7713193</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Am J Pathol. 1996 Feb;148(2):657-66</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">8579128</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Exp Med. 1996 Dec 1;184(6):2429-32</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">8976199</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Trends Biotechnol. 1997 May;15(5):178-85</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9161052</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Virol. 1997 Dec;71(12):9450-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9371606</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Immunol Rev. 1997 Oct;159:105-17</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9416506</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Immunol. 1997 Dec 1;159(11):5197-200</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9548456</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>CMAJ. 2004 Nov 23;171(11):1349-52</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15557587</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Virus Res. 2005 Jan;107(1):93-101</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15567038</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Front Biosci. 2005 Jan 1;10:582-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15569599</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Microbes Infect. 2004 Dec;6(15):1382-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15596124</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Adv Immunol. 2005;86:241-305</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15705424</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Antiviral Res. 2005 Feb;65(2):87-95</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15708635</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Virology. 2005 Apr 25;335(1):34-45</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15823604</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001811 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 001811 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    PubMed
   |étape=   Curation
   |type=    RBID
   |clé=     pubmed:19851468
   |texte=   Evasion by stealth: inefficient immune activation underlies poor T cell response and severe disease in SARS-CoV-infected mice.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i   -Sk "pubmed:19851468" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd   \
       | NlmPubMed2Wicri -a SrasV1 

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021